I
mmunotherapy is a potentially attractive treatment option for patients with hepatocellular carcinoma (HCC). We have reported that glypican-3 (GPC3) is an ideal target for anticancer immunotherapy against HCC because its expression is specifically detected in > 80% of HCCs, even during the early stages. Further, increased GPC3 expression is correlated with a poor prognosis. Based on results obtained from a preclinical study using mice, we conducted a phase I clinical trial using a GPC3-derived peptide vaccine. Phase I results showed that the GPC3-derived peptide vaccine was well tolerated. Furthermore, this was the first study to show that the frequency of peptide-specific cytotoxic T lymphocytes was correlated with overall survival in patients with HCC receiving a peptide vaccine. Next, we conducted a phase II clinical trial using the GPC3-derived peptide vaccine in patients with HCC after surgery or radiofrequency ablation (adjuvant setting). We are currently evaluating a third trial involving liver biopsies removed from patients with advanced HCC before and after GPC3-derived peptide vaccination. We expect that the results of these trials will result in future drug development.
Introduction
Primary liver cancer, which predominantly consists of hepatocellular carcinoma (HCC), is an aggressive form of cancer that has a poor prognosis, 1 no second-line treatment has been established for patients who do not respond to sorafenib treatment. Therefore, new treatment modalities are urgently required to prolong the survival of patients with advanced HCC.
Immunotherapy is a potentially attractive option for treating HCC, and the induction of tumor-specific reactions without autoimmunity is the ideal strategy. Recently, antigen-specific cancer immunotherapies against HCC, including peptide vaccines, dendritic cell vaccines and adoptive cell transfer therapies have attracted much interest. However, most previous clinical trials have not demonstrated adequate proof of immunotherapy efficacy for advanced HCC. 4, 5 On the other hand, our clinical trial of glypican-3(GPC3)-derived peptide vaccine against advanced HCC demonstrated that the induction of peptide-specific cytotoxic T lymphocytes (CTLs) significantly correlated with patient survival. 6 Here, we summarize recent advances and future directions of peptide vaccines for the treatment of HCC.
Basic and Preclinical Studies Using GPC3 for the Treatment of HCC
GPC3 belongs to the glypican family of heparan sulfate proteoglycans, which are linked to the outer surface of the cell membrane through a glycosylphosphatidylinositol anchor. 7 We reported its identification as a carcinoembryonic antigen and an ideal target for anticancer immunotherapy against HCC due to its specific overexpression in HCC (> 80%). 8 The GPC3 peptide-specific CTL frequency in peripheral blood was significantly correlated with overall survival in patients with HCC who received the peptide vaccination. In a multivariate analysis, the frequency of GPC3 peptidespecific CTLs was a predictive factor for overall survival. An analysis of all 33 patients showed that the median overall survival was 12.2 mo (95% CI, 6.5-18.0) in patients with high GPC3-specific CTL frequencies, as compared with 8.5 mo (95% CI, 3.7-13.1) in those with low GPC3-specific CTL frequencies (p = 0.033) (Fig. 1) . These observations suggest that GPC3-derived peptide vaccines represent a novel therapy for patients with HCC, with the potential to improve overall survival.
Phase II Trial of the GPC3-Derived Peptide Vaccine for Treatment of HCC
In the phase I trial, the GPC3-derived peptide vaccines showed remarkable efficacy against advanced HCC. On the other hand, immunotherapy is expected to contribute toward cancer therapy, especially during the early stages or in recurrence prevention. Therefore, we conducted a phase II clinical trial of the GPC3-derived peptide vaccine in the adjuvant setting (UMIN-CTR: 000002614). Forty patients with initial HCC who had undergone surgery or radiofrequency ablation were enrolled in this phase II, open-label, single-arm trial. Ten 3-mg GPC3-derived peptide vaccinations were performed over 1 y following curative treatment. The primary endpoints were the 1-and 2-y recurrence rates. The secondary endpoints were immunological responses. Currently, the correlation between the time of recurrence and immunological responses is being analyzed.
In the phase I trial, we did not confirm whether the tumor-infiltrating lymphocytes detected after vaccination were GPC3-peptide-specific CTLs. Therefore, we are initiating a pilot study of liver biopsies removed from patients with advanced HCC before and after GPC3 peptide vaccination (UMIN-CTR: 000005093).
We expect that the results of these trials will provide a rationale for a larger treated with the GPC3 144-152 (FVG EFF TDV) peptide.
The primary endpoint was peptide vaccination safety. The secondary endpoints were immunologic responses, clinical outcomes and determination of the optimal peptide dose for further clinical trials. The trial was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR number, 000001395).
GPC3-derived peptide vaccination was well tolerated. One patient showed a partial response (PR) and 4 of the 19 patients with stable disease (SD) had tumor necrosis or regression that did not meet the criteria for a PR. The disease control rate (PR+SD) was 60.6% at 2 mo after the initiation of treatment. We also analyzed the GPC3-specific CTL frequency ex vivo using the interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) assay. In most patients, GPC3 peptidespecific CTLs appeared in the peripheral blood. Furthermore, we established several GPC3 [144] [145] [146] [147] [148] [149] [150] [151] [152] peptide-specific CTL clones with antigen-specific killing activity against tumor cells from peripheral blood mononuclear cells (PBMCs) obtained from patients vaccinated in this trial.
14 Tumor biopsies were performed in 7 patients to evaluate infiltration of CD8-positive T cells by immunohistochemical staining; marked infiltration of CD8-positive T cells into the tumor was detected after vaccination in 5 patients.
and H-2K
d -restricted GPC3 298-306 (EYI LSL EEL), as well as HLA-A2(A*02:01)-restricted GPC3 144-152 (FVG EFF TDV), as peptides that can induce GPC3-reactive CTLs without inducing autoimmunity. 9, 12 Using binding assays, we confirmed that the HLA-A*02:01-restricted GPC3 [144] [145] [146] [147] [148] [149] [150] [151] [152] (FVG EFF TDV) peptide can also bind to HLA-A*02:06 and HLA-A*02:07. Using a mouse model to determine the optimal treatment schedule for the GPC3-derived peptide vaccines, we showed that incomplete Freund's adjuvant (IFA) is indispensable for peptide-based immunotherapy, and that the immunological effects of the peptide vaccine were dose-dependent. 
